Patents by Inventor Brian Scott Johnathan Blagg

Brian Scott Johnathan Blagg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of DYRK1A kinase
    Patent number: 11603343
    Abstract: Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each six-membered ring includes at least one oxygen-bearing substituent selected from carbonyl oxygens, hydroxyls, alkoxyls, and halogenated derivatives thereof. The compounds can be administered to mammalian subjects for inhibition of DYRK1A kinase proteins.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: March 14, 2023
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Brian Scott Johnathan Blagg, Cameron E. West
  • INHIBITION OF DYRK1A KINASE
    Publication number: 20220064091
    Abstract: Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each six-membered ring includes at least one oxygen-bearing substituent selected from carbonyl oxygens, hydroxyls, alkoxyls, and halogenated derivatives thereof. The compounds can be administered to mammalian subjects for inhibition of DYRK1A kinase proteins.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 3, 2022
    Applicant: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Brian Scott Johnathan Blagg, Cameron E. West
  • Fused polycyclic dimers
    Patent number: 10947253
    Abstract: Novel fused tricyclic or bicyclic dimers, such as ?-carboline and quinoline moieties with a central linker, exhibit anti-cancer activities against a variety of human cancer cell lines. The dimer compounds can be used in anti-cancer therapeutic compositions useful in the treatment of human cancers.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 16, 2021
    Assignee: Ankh Life Sciences Limited
    Inventors: Brian Scott Johnathan Blagg, Vishal Chandrakumar Birar, Gene H. Zaid
  • FUSED POLYCYCLIC DIMERS
    Publication number: 20210040121
    Abstract: Novel fused tricyclic or bicyclic dimers, such as ?-carboline and quinoline moieties with a central linker, exhibit anti-cancer activities against a variety of human cancer cell lines. The dimer compounds can be used in anti-cancer therapeutic compositions useful in the treatment of human cancers.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 11, 2021
    Applicant: Ankh Life Sciences Limited
    Inventors: Brian Scott Johnathan Blagg, Vishal Chandrakumar Birar, Gene H. Zaid